Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin‐receptor ligand trap RAP‐536 in β‐thalassemic mice
American Journal of Hematology · 2024
DOI: 10.1002/ajh.27336 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Emanuele Tanzi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Regulation of Iron Metabolism Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: beta-Thalassemia, Receptors, Transferrin, Recombinant Fusion Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Celgene, Cariplo Foundation, Fondazione Cariplo.
Abstract (Originalsprache)
β‐thalassemia is a disorder characterized by anemia, ineffective erythropoiesis (IE), and iron overload, whose treatment still requires improvement. The activin receptor‐ligand trap Luspatercept, a novel therapeutic option for β‐thalassemia, stimulates erythroid differentiation inhibiting the transforming growth factor β pathway. However, its exact mechanism of action and the possible connection with erythropoietin ( Epo ), the erythropoiesis governing cytokine, remain to be clarified. Moreover, Luspatercept does not correct all the features of the disease, calling for the identification of strategies that enhance its efficacy. Transferrin receptor 2 (TFR2) regulates systemic iron homeostasis in the liver and modulates the response to Epo of erythroid cells, thus balancing red blood cells production with iron availability. Stimulating Epo signaling, hematopoietic Tfr2 deletion ameliorates anemia and IE in Hbb th3 / + thalassemic mice. To investigate whether hematopoietic Tfr2 inactivation improves the efficacy of Luspatercept, we treated Hbb th3 / + mice with or without hematopoietic Tfr2 ( Tfr2 BMKO /Hbb th3 / + ) with RAP‐536, the murine analog of Luspatercept. As expected, both hematopoietic Tfr2 deletion and RAP‐536 significantly ameliorate IE and anemia, and the combined approach has an additive effect. Since RAP‐536 has comparable efficacy in both Hbb th3/+ and Tfr2 BMKO /Hbb th3/+ animals, we propose that the drug promotes erythroid differentiation independently of TFR2 and EPO stimulation. Notably, the lack of Tfr2 , but not RAP‐536, can also attenuate iron‐overload and related complications. Overall, our results shed further light on the mechanism of action of Luspatercept and suggest that strategies aimed at inhibiting hematopoietic TFR2 might improve the therapeutic efficacy of activin receptor‐ligand traps.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Regulation of Iron Metabolism Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- B-cell Neoplasia Unit, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
ORCID-Profile: Jessica Bordini, Laura Silvestri, Alessandro Campanella, Antonella Nai
Förderung
- Celgene
- Cariplo Foundation
- Fondazione Cariplo
Zitieren
APA
Tanzi, E., Di Modica, S. M., Bordini, J., Olivari, V., Pagani, A., Furiosi, V., Silvestri, L., Campanella, A., & Nai, A. (2024). Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin‐receptor ligand trap RAP‐536 in β‐thalassemic mice. American Journal of Hematology. https://doi.org/10.1002/ajh.27336
Vancouver
Tanzi E, Di Modica SM, Bordini J, Olivari V, Pagani A, Furiosi V, et al. Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin‐receptor ligand trap RAP‐536 in β‐thalassemic mice. American Journal of Hematology. 2024. doi:10.1002/ajh.27336
BibTeX
@article{Tanzi2024,
author = {Tanzi, Emanuele and Di Modica, Simona Maria and Bordini, Jessica and Olivari, Violante and Pagani, Alessia and Furiosi, Valeria and Silvestri, Laura and Campanella, Alessandro and Nai, Antonella},
title = {Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin‐receptor ligand trap RAP‐536 in β‐thalassemic mice},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.27336}
}
EUVIMED